Recurrence

Organ transplant recipients diagnosed with cutaneous squamous cell carcinoma are more likely to experience recurrence, metastasis and death from this cancer compared with non-organ transplant recipients, according to a study.

In a small group of adults diagnosed with medullary thyroid microcarcinoma, few had disease recurrence or died during more than 6 years of follow-up, according to findings from an Australian database.

A deep learning model accurately identified women with endometrial cancer at low and high risk for distant recurrence, according to research presented at American Association for Cancer Research Annual Meeting.

Black and Asian women with early-stage, hormone-receptor positive, HER2-negative, node-negative breast cancer appeared about twice as likely as their white counterparts to experience locoregional recurrence.

The addition of ribociclib to adjuvant endocrine therapy significantly reduced the risk for disease recurrence among patients with hormone receptor-positive, HER2-negative early breast cancer, according to the agent’s manufacturer.

Low household income appeared independently associated with higher 21-gene recurrence scores and significantly worse survival outcomes among women with ER-positive breast cancer, according to data published in JAMA Network Open.

Breast cancer stage and receptor status appeared to predict risk for recurrence among patients with stage I to stage III disease, according to study results published in Cancer.

Mohs micrographic surgery decreased recurrence rates and increased survival among patients with head and neck melanoma compared with conventional excision, according to a study.

Adjuvant therapy with atezolizumab and bevacizumab reduced recurrence risk compared with active surveillance for patients with certain types of early-stage liver cancer, according to topline data released by the agents’ manufacturer.

A study conducted at University of Pennsylvania’s Abramson Cancer Center has revealed possible drivers of recurrence in breast and ovarian tumors with BRCA1/BRCA2 mutations.